Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 4 de 4
Filtre
Ajouter des filtres








Gamme d'année
1.
Clinical Psychopharmacology and Neuroscience ; : 415-421, 2018.
Article Dans Anglais | WPRIM | ID: wpr-718219

Résumé

OBJECTIVE: Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by impairment in social skills and communication with repetitive behaviors. Etiology is still unclear although it is thought to develop with interaction of genes and environmental factors. Oxytocin has extensive effects on intrauterine brain development. Vitamin D, affects neural development and differentiation and contributes to the regulation of around 900 genes including oxytocin receptor gene. In the present study, the contribution of D vitamin receptor and oxytocin receptor gene polymorphisms in the development of ASD in Turkish community was investigated. To our knowledge, this is the first study examining these two associated genes together in the literature. METHODS: Eighty-five patients diagnosed with ASD according to DSM-5 who were referred to outpatient clinics of Child and Adolescent Psychiatry of Başkent University and Mersin University and 52 healthy, age and gender-matched controls were included in the present study. Vitamin D receptor gene rs731236 (Taq1), rs2228570 (Fok1), rs1544410 (Bsm1), rs7975232 (Apa1) polymorphisms and oxytocin receptor gene rs1042778 and rs2268493 polymorphisms were investigated using real time polymerase chain reaction method. RESULTS: No significant difference between groups in terms of distribution of genotype and alleles in each of polymorphisms for these genes could be found. CONCLUSION: Knowledge of genes and polymorphisms associated with the development of ASD may be beneficial for early diagnosis and future treatment. Further studies with larger populations are required to demonstrate molecular pathways which may play part in the development of ASD in Turkey.


Sujets)
Adolescent , Enfant , Humains , Psychiatrie de l'adolescent , Allèles , Établissements de soins ambulatoires , Trouble du spectre autistique , Encéphale , Diagnostic précoce , Génotype , Méthodes , Troubles du développement neurologique , Ocytocine , Polymorphisme génétique , Réaction de polymérisation en chaine en temps réel , Récepteur calcitriol , Récepteurs à l'ocytocine , Compétences sociales , Turquie , Vitamine D , Vitamines
2.
Clinical Psychopharmacology and Neuroscience ; : 343-345, 2018.
Article Dans Anglais | WPRIM | ID: wpr-716366

Résumé

Amenorrhea, oligomenorrhea, galactorrhoea, gynecomastia, infertility, and sexual dysfunction may arise as a consequence of hyperprolactinemia. Hyperprolactinemia is one of major side effects of treatment with antipsychotics, but aripiprazole is known as a dopamine stabilizer antipsychotic which can be used to improve hyperprolactinemia. In this report, it was described that an adolescent patient experienced amenorrhea after adding very low dose aripiprazole to ongoing fluoxetine treatment regime for major depressive disorder. Additionally, this case showed that the patient recovered from the amenorrhea with replacement of aripiprazole with quetiapine.


Sujets)
Adolescent , Femelle , Humains , Mâle , Aménorrhée , Neuroleptiques , Aripiprazole , Trouble dépressif majeur , Dopamine , Fluoxétine , Gynécomastie , Hyperprolactinémie , Infertilité , Oligoménorrhée , Fumarate de quétiapine
3.
Clinical Psychopharmacology and Neuroscience ; : 410-412, 2017.
Article Dans Anglais | WPRIM | ID: wpr-58952

Résumé

Our case had hiccups arising in an adolescent with the attention deficit and hyperactivity disorder (ADHD) and conduct disorder (CD) after adding aripiprazole treatment to extended-release methylphenidate. Actually, antipsychotics are also used in the treatment of hiccups, but studies suggest that they can cause hiccups as well. Within 12 hours of taking 2.5 mg aripiprazole added to extended-release methylphenidate at a dose of 54 mg/day, 16-year-old boy began having hiccups in the morning, which lasted after 3–4 hours. As a result, aripiprazole was discontinued and methylphenidate was continued alone because we could not convince the patient to use another additional drug due to this side effect. Subsequently, when his behavior got worsened day by day, his mother administered aripiprazole alone again at the dose of 2.5 mg/day at the weekend and continued treatment because hiccup did not occur again. But when it was administered with methylphenidate on Monday, hiccup started again next morning and lasted one hour at this time. In conclusion, we concluded that concurrent use of methylphenidate and aripiprazole in this adolescent led to hiccups.


Sujets)
Adolescent , Humains , Mâle , Neuroleptiques , Aripiprazole , Trouble de la conduite , Cytochrome P-450 CYP2D6 , Hoquet , Méthylphénidate , Mères
4.
Clinical Psychopharmacology and Neuroscience ; : 115-117, 2015.
Article Dans Anglais | WPRIM | ID: wpr-167397

Résumé

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder with common comorbidities that include oppositional defiant disorder, conduct disorder, anxiety disorder, and affective disorders. Because of these comorbidities, drug combination treatments and drug-drug interactions are becoming increasingly more frequent. The present case report describes an acute dystonic reaction following the abrupt discontinuation of methylphenidate from a drug regimen with risperidone. The patient experienced acute dystonic reactions on three separate occasions when he forgot to take his methylphenidate medication. The present report informs clinicians about the possible side effects, such as dystonia, when psychostimulant and antipsychotic drug combinations are altered and suggests that the abrupt cessation of stimulants may lead to the development of movement disorders. Therefore, appropriate care is necessary when changing the dose of a drug or abruptly discontinuing a drug from a combination of psychostimulants and antipsychotics.


Sujets)
Adolescent , Humains , Neuroleptiques , Troubles anxieux , Troubles déficitaires de l'attention et du comportement perturbateur , Comorbidité , Trouble de la conduite , Association médicamenteuse , Dystonie , Méthylphénidate , Troubles de l'humeur , Troubles de la motricité , Rispéridone
SÉLECTION CITATIONS
Détails de la recherche